Saying we need to try to stay ahead of a virus and not behind it, the CEO of Moderna says the company is working on an Omicron-specific booster shot.

Stephane Bance says it’s about to go into clinical trials and could be in pharmacies and arms as early as this fall.

Modern’s current booster; a half dose, increases neutralizing antibody levels against Omicron 37-fold over the second shot.

A full dose increases effectiveness 100-fold.

The company has already reached purchase agreements worth $18.5-billion with the U.K., South Korea and Switzerland for shots as soon as they’re available.

The CEO says the struggle’s been getting the vaccine to less developed countries.

Of the more than 800-million doses Moderna has delivered so far, only about one-quarter have gone to low- and middle-income countries.